Overview

Evaluate Bioequivalence of Micafungin (50mg/Vial)

Status:
Completed

Trial end date:
2022-07-28

Target enrollment:

Participant gender:

Summary

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of micafungin (50 mg/vial) after intravenous infusion of 50 mg micafungin in healthy volunteers under fasting conditions

Phase:

Phase 4

Details

Lead Sponsor:

Yung Shin Pharm. Ind. Co., Ltd.

Treatments:

Micafungin